Drug intelligence / Profile preview

ziprasidone + risperidone + olanzapine

Development stage: Preclinical
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral, Intramuscular

Overview

This is a combination of three atypical antipsychotic medications (ziprasidone, risperidone, and olanzapine) that may be used in the treatment of schizophrenia and other psychotic disorders. While these medications are sometimes used in combination therapy, particularly when monotherapy is ineffective, they are not typically formulated together as a single product. Each drug has its own mechanism of action involving antagonism of dopamine and serotonin receptors, though with different receptor binding profiles and side effect patterns.

Targets

HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on ziprasidone + risperidone + olanzapine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ziprasidone + risperidone + olanzapine.

Explore the full profile